Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

le allowing Isis to continue to benefit as future milestones and commercial revenues are realized. By working closely with OncoGenex during the development of OGX-011, we have confidence that OncoGenex will independently maximize the value of OGX-011."

"The contributions of Isis have been instrumental in the development of OGX-011 to date and we anticipate that our positive interactions will continue with this amended relationship," added Cormack.

Under the terms of the original co-development agreement, OncoGenex paid 65% of the development costs and would receive 65% of any economic benefit resulting from the development of OGX-011. Under the terms of the amended agreement, Isis' funding commitment for 35% of the OGX-011 program ends, and OncoGenex will be responsible for all future development costs of OGX-011. These expenses have already been factored into OncoGenex' previously announced disclosures regarding anticipated development costs. Isis will receive royalties for OGX-011 ranging from 5.5% to 7% of net sales. In addition, OncoGenex will pay Isis 30% of the upfront fees and milestone payments OncoGenex receives if OncoGenex licenses OGX-011 prior to initiation of registration trials, 25% if OGX-011 is licensed before 20% of patients have been enrolled in a registration trial, 20% if OGX-011 is licensed prior to marketing approval and 15% thereafter.

OncoGenex recently announced preliminary Phase 2 data of OGX-011 in patients with hormone refractory prostate cancer at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). Investigators found that, in this patient population, OGX-011 continues to show better than expected survival results when compared to published results. OGX-011, also referred to as custirsen sodium, is a second-generation antisense oligonucleotide designed to facilitate tumor cell death induced by chemotherapy by decreasing production of clusterin, a cell survival protein linked to treatment res
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
(Date:7/29/2015)... DUBLIN , July 29, 2015 ... ) has announced the addition of the ... to their offering. The Global Biosimilars ... study of the rapidly growing biosimilars market. With ... industry striving to minimize costs, biosimilars are being ...
(Date:7/29/2015)... July 29, 2015  Therapath Neuropathology ( www.Therapath.com ... partnerships with VA and Military Medical centers both ... Density (ENFD) and Sweat Gland Nerve Fiber Density ... ( https://therapath.com/skin ). Demonstration of ... (ENFD) on punch skin biopsy is a highly ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the ... system received a score of 0 (range -10 to +10) for its impact on ... Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes to ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... Former Wisconsin Governor and U.S. Department of Health and ... World Congress on Information Technology at its annual ... Deloitte Center for Health Solutions , will speak during a ... addition to healthcare, the other main topics will be Privacy ...
... line of reports paints a bleak picture for entrepreneurs ... could be at its lowest level in 10 years ... end. , ,The Money Tree Survey , released ... National Venture Capital Association, indicates that, unless millions of ...
... Source: http://www.bootstrapit.com/ 1. Bootstrapping ensures that ... proposition. When youre bootstrapping, youre forced to deal with ... If you have a lot of external funding, on ... youve already created an actual business just because youre ...
Cached Biology Technology:While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 2While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 3While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 4Greg Gianfortes Bootstrapping Principles 2Greg Gianfortes Bootstrapping Principles 3
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Associate Professor Paul Blowers of the University of Arizona ... Arizona Professor of the Year, recognized for commitment to ... of Teaching and the Council for Advancement and Support ... the award on Nov. 17 in Washington, D.C. ...
... beauty of science often is contained in elegant formulas ... fortunately, that beauty also is manifest in enticing images ... also provide important scientific insights into the complex flow ... Every year, the American Physical Society,s (APS) Division ...
... recent report in Cancer Discovery , a journal ... a new treatment may be on the horizon for ... disease. Mark Rubin, M.D., professor of pathology and ... fewer than 2 percent of men with prostate cancer ...
Cached Biology News:Arizona Engineering associate professor earns national recognition 2
...
CD45/CD34 combination 50 tests...
... Rabbit polyclonal to ThPok ( Abpromise for ... Synthetic peptide conjugated to KLH derived from within ... (Note: the amino acid sequence is proprietary) ... .) Entrez Gene ID: ...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Biology Products: